OTC-QX:ORXOY

Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product

Retrieved on: 
Tuesday, August 29, 2023
United States Patent and Trademark Office, Patent, ORX, Allergy, Emergency, Patient, Pharmaceutical industry, Orexo

), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.
  • Orexo continues to strengthen its patent portfolio and the new patent, No.
  • US 11,737,980, provides protection for the OX640 product in the US until May 2041.
  • Last year, a European patent was granted, and multiple patent applications have been filed by Orexo protecting OX640 on a global basis until 2044.

Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product

Retrieved on: 
Tuesday, August 29, 2023
United States Patent and Trademark Office, Patent, ORX, Allergy, Emergency, Patient, Pharmaceutical industry, Orexo

), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.
  • Orexo continues to strengthen its patent portfolio and the new patent, No.
  • US 11,737,980, provides protection for the OX640 product in the US until May 2041.
  • Last year, a European patent was granted, and multiple patent applications have been filed by Orexo protecting OX640 on a global basis until 2044.

Orexo's patent win for ZUBSOLV® appealed

Retrieved on: 
Monday, July 24, 2023
US Foods, Abbreviated New Drug Application, United States Court of Appeals for the Federal Circuit, The Orange Book, Naloxone, Sun Pharma, Buprenorphine, Sun, SUN, ORX, Orexo, CIII, SEK, Tablet, United States district court, Orange Book, District court, Patent, United States District Court for the Eastern District of Texas, Food, Generic drug, Appeal

The litigation was initiated in September 2020 because of Sun's submission of an Abbreviated New Drug Application with the US Food and Drug Administration seeking approval of generic versions of ZUBSOLV®.

Key Points: 
  • The litigation was initiated in September 2020 because of Sun's submission of an Abbreviated New Drug Application with the US Food and Drug Administration seeking approval of generic versions of ZUBSOLV®.
  • Sun has now appealed the district court's decision to the US Court of Appeals for the Federal Circuit.
  • We remain very confident in the strength of the patent portfolio and that the Court of Appeals will come to the same conclusion."
  • ZUBSOLV® is currently protected by ten patents listed in the Orange Book with expiration dates ranging from December 2027 to September 2032.

Orexo's patent win for ZUBSOLV® appealed

Retrieved on: 
Monday, July 24, 2023
US Foods, Abbreviated New Drug Application, United States Court of Appeals for the Federal Circuit, The Orange Book, Naloxone, Sun Pharma, Buprenorphine, Sun, SUN, ORX, Orexo, CIII, SEK, Tablet, United States district court, Orange Book, District court, Patent, United States District Court for the Eastern District of Texas, Food, Generic drug, Appeal

The litigation was initiated in September 2020 because of Sun's submission of an Abbreviated New Drug Application with the US Food and Drug Administration seeking approval of generic versions of ZUBSOLV®.

Key Points: 
  • The litigation was initiated in September 2020 because of Sun's submission of an Abbreviated New Drug Application with the US Food and Drug Administration seeking approval of generic versions of ZUBSOLV®.
  • Sun has now appealed the district court's decision to the US Court of Appeals for the Federal Circuit.
  • We remain very confident in the strength of the patent portfolio and that the Court of Appeals will come to the same conclusion."
  • ZUBSOLV® is currently protected by ten patents listed in the Orange Book with expiration dates ranging from December 2027 to September 2032.

Report from Orexo AB's annual general meeting

Retrieved on: 
Tuesday, April 18, 2023
LTIP, Tax, Acquisition, SEK, Speech, Holding company, Management, Orexo

The annual general meeting also resolved on fees to the board of directors in accordance with the nomination committee's proposal.

Key Points: 
  • The annual general meeting also resolved on fees to the board of directors in accordance with the nomination committee's proposal.
  • The annual general meeting resolved to adopt procedures for the appointment of the nomination committee for the annual general meeting 2024 substantially in accordance with the same procedure as the preceding year.
  • The annual general meeting resolved, in accordance with the board's proposal, to adopt a new long-term incentive program for not more than 130 selected employees within the Orexo group, LTIP 2023.
  • LTIP 2023 substantially corresponds with LTIP 2022, a performance based long-term incentive program adopted at the annual general meeting 2022.

Report from Orexo AB's annual general meeting

Retrieved on: 
Tuesday, April 18, 2023
LTIP, Tax, Acquisition, SEK, Speech, Holding company, Management, Orexo

The annual general meeting also resolved on fees to the board of directors in accordance with the nomination committee's proposal.

Key Points: 
  • The annual general meeting also resolved on fees to the board of directors in accordance with the nomination committee's proposal.
  • The annual general meeting resolved to adopt procedures for the appointment of the nomination committee for the annual general meeting 2024 substantially in accordance with the same procedure as the preceding year.
  • The annual general meeting resolved, in accordance with the board's proposal, to adopt a new long-term incentive program for not more than 130 selected employees within the Orexo group, LTIP 2023.
  • LTIP 2023 substantially corresponds with LTIP 2022, a performance based long-term incentive program adopted at the annual general meeting 2022.

Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124

Retrieved on: 
Monday, April 3, 2023
US Foods, Life, NDA, ORX, Orexo, Documentation, FDA, Food, Pharmaceutical industry, Medical device

As a result, FDA has requested Orexo to resubmit a New Drug Application (NDA), when Orexo has completed the qualification and can confirm the packaging process is ready for FDA inspection.

Key Points: 
  • As a result, FDA has requested Orexo to resubmit a New Drug Application (NDA), when Orexo has completed the qualification and can confirm the packaging process is ready for FDA inspection.
  • I am disappointed with the delay in the process of bringing this life saving medication to the US market.
  • When solved, this will even further strengthen the supply chain for our future rescue medications, such as OX640 and OX125."
  • On February 3, 2023, Orexo submitted the NDA with the FDA for OX124.

Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124

Retrieved on: 
Monday, April 3, 2023
US Foods, Life, NDA, ORX, Orexo, Documentation, FDA, Food, Pharmaceutical industry, Medical device

As a result, FDA has requested Orexo to resubmit a New Drug Application (NDA), when Orexo has completed the qualification and can confirm the packaging process is ready for FDA inspection.

Key Points: 
  • As a result, FDA has requested Orexo to resubmit a New Drug Application (NDA), when Orexo has completed the qualification and can confirm the packaging process is ready for FDA inspection.
  • I am disappointed with the delay in the process of bringing this life saving medication to the US market.
  • When solved, this will even further strengthen the supply chain for our future rescue medications, such as OX640 and OX125."
  • On February 3, 2023, Orexo submitted the NDA with the FDA for OX124.

Orexo postpones publication of the Annual Report

Retrieved on: 
Wednesday, March 15, 2023
Annual report, ORX, Orexo, Online shopping, Auction, ESEF

UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023.

Key Points: 
  • UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023.
  • The previously announced date for publication was March 24, 2023.
  • The change in date is due to prolonged audit of the financial reporting in the European Single Electronic Format, ESEF.
  • For further information please contact:

Orexo postpones publication of the Annual Report

Retrieved on: 
Wednesday, March 15, 2023
Annual report, ORX, Orexo, Online shopping, Auction, ESEF

UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023.

Key Points: 
  • UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023.
  • The previously announced date for publication was March 24, 2023.
  • The change in date is due to prolonged audit of the financial reporting in the European Single Electronic Format, ESEF.
  • For further information please contact: